Equities analysts expect uniQure (NASDAQ:QURE – Get Rating) to post earnings of ($0.61) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for uniQure’s earnings, with estimates ranging from ($1.20) to $1.16. uniQure posted earnings of ($0.91) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 33%. The firm is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that uniQure will report full-year earnings of ($2.66) per share for the current fiscal year, with EPS estimates ranging from ($4.30) to ($0.21). For the next year, analysts anticipate that the business will report earnings of ($2.30) per share, with EPS estimates ranging from ($3.85) to $0.42. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for uniQure.
uniQure (NASDAQ:QURE – Get Rating) last announced its quarterly earnings results on Friday, February 25th. The biotechnology company reported $0.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.89. The business had revenue of $57.69 million for the quarter, compared to analyst estimates of $25.12 million. uniQure had a return on equity of 64.35% and a net margin of 62.90%.
uniQure stock traded up $0.36 on Tuesday, reaching $18.81. The company’s stock had a trading volume of 15,146 shares, compared to its average volume of 473,702. The company has a debt-to-equity ratio of 0.17, a quick ratio of 17.09 and a current ratio of 17.09. uniQure has a twelve month low of $14.29 and a twelve month high of $38.80. The stock has a market capitalization of $873.91 million, a P/E ratio of 2.70 and a beta of 1.05. The company’s fifty day moving average is $17.10.
In related news, CFO Christian Klemt sold 4,075 shares of the company’s stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $16.80, for a total value of $68,460.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 10,195 shares of the firm’s stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $16.70, for a total value of $170,256.50. The disclosure for this sale can be found here. Insiders sold a total of 40,111 shares of company stock valued at $698,006 in the last 90 days. 2.66% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the company. Morgan Stanley grew its position in uniQure by 114.4% during the second quarter. Morgan Stanley now owns 105,734 shares of the biotechnology company’s stock valued at $3,256,000 after acquiring an additional 56,427 shares during the period. Hudson Bay Capital Management LP grew its stake in uniQure by 12.5% during the 3rd quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company’s stock worth $8,323,000 after buying an additional 28,900 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of uniQure during the third quarter valued at approximately $1,062,000. New York State Teachers Retirement System acquired a new stake in uniQure in the third quarter worth about $301,000. Finally, Handelsbanken Fonder AB raised its stake in shares of uniQure by 55.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 11,800 shares of the biotechnology company’s stock worth $378,000 after buying an additional 4,200 shares in the last quarter. 81.40% of the stock is owned by institutional investors and hedge funds.
uniQure Company Profile (Get Rating)
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
- Tilray Stock Has Better Days Ahead
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.